HK1164159A1 - A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib - Google Patents

A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib

Info

Publication number
HK1164159A1
HK1164159A1 HK12105129.9A HK12105129A HK1164159A1 HK 1164159 A1 HK1164159 A1 HK 1164159A1 HK 12105129 A HK12105129 A HK 12105129A HK 1164159 A1 HK1164159 A1 HK 1164159A1
Authority
HK
Hong Kong
Prior art keywords
sunitinib
sorafenib
erlotinib
quinolin
pyrrolo
Prior art date
Application number
HK12105129.9A
Other languages
English (en)
Inventor
Thomas C K Chan
Dennis S France
Kenichi Ishii
Paolo Pucci
Original Assignee
Arqule Inc
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc, Kyowa Hakko Kirin Co Ltd filed Critical Arqule Inc
Publication of HK1164159A1 publication Critical patent/HK1164159A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12105129.9A 2009-02-12 2012-05-24 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib HK1164159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15213809P 2009-02-12 2009-02-12
US17047109P 2009-04-17 2009-04-17
PCT/US2010/023893 WO2010093789A2 (fr) 2009-02-12 2010-02-11 Compositions combinatoires et procédés pour le traitement du cancer

Publications (1)

Publication Number Publication Date
HK1164159A1 true HK1164159A1 (en) 2012-09-21

Family

ID=42126095

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105129.9A HK1164159A1 (en) 2009-02-12 2012-05-24 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib

Country Status (14)

Country Link
US (2) US20100297075A1 (fr)
EP (1) EP2396003B1 (fr)
JP (1) JP5687209B2 (fr)
KR (1) KR101620654B1 (fr)
CN (1) CN102481299B (fr)
AU (1) AU2010213696B2 (fr)
BR (1) BRPI1007972A2 (fr)
CA (1) CA2752232C (fr)
HK (1) HK1164159A1 (fr)
IL (1) IL214348A (fr)
MX (1) MX2011008584A (fr)
TW (1) TWI460178B (fr)
WO (1) WO2010093789A2 (fr)
ZA (1) ZA201105611B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396003B1 (fr) 2009-02-12 2013-04-17 ArQule, Inc. Compositions comprenant du (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione et du sorafenib, sunitinib ou de l'erlotinib
WO2012003421A2 (fr) 2010-07-01 2012-01-05 Arqule, Inc. Compositions et procédés combinatoires de traitement du cancer
TW201221126A (en) 2010-09-01 2012-06-01 Arqule Inc Methods for treatment of non-small cell lung cancer
US8709420B2 (en) * 2010-12-17 2014-04-29 Glaxosmithkline Intellectual Property Limited Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
US8470786B2 (en) * 2010-12-23 2013-06-25 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
JP6253991B2 (ja) * 2011-03-02 2017-12-27 ジェローム シェンターク， 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
AU2012278831A1 (en) 2011-07-07 2014-01-16 Arqule, Inc Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CA2846630A1 (fr) * 2011-09-19 2013-03-28 Genentech, Inc. Polytherapies comportant des antagonistes de c-met et de b-raf
WO2013085902A1 (fr) * 2011-12-05 2013-06-13 The University Of Texas M.D. Procédés de polythérapie pour le traitement d'un cancer du sein inflammatoire
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
EP2841069A4 (fr) * 2012-04-23 2015-09-02 Arqule Inc Pyrroloquinolinyl-pyrrole-2,5-dione et pyrroloquinolinyl-pyrrolidine-2,5-dione de pureté élevée et leurs procédés de préparation
CN102757435B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
RU2715229C2 (ru) * 2015-12-07 2020-02-26 Хинова Фармасьютикалс Инк. Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
KR20210135354A (ko) 2017-02-15 2021-11-12 다이호야쿠힌고교 가부시키가이샤 의약 조성물
CN108546244B (zh) * 2018-07-05 2021-04-23 南昌航空大学 一种3,3’-二吲哚乙烷类化合物的合成方法
US20240058335A1 (en) * 2021-01-08 2024-02-22 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway
WO2024105699A1 (fr) * 2022-11-18 2024-05-23 Council Of Scientific And Industrial Research Composition pour le traitement du cancer du sein résistant au paclitaxel et son procédé de préparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DK1846406T5 (da) * 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
CA2683559C (fr) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methodes de traitement d'un cancer resistant a des agents therapeutiques anti-erbb
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
CA2702637A1 (fr) 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entierement humains et leurs procedes d'utilisation
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
EP2396003B1 (fr) 2009-02-12 2013-04-17 ArQule, Inc. Compositions comprenant du (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione et du sorafenib, sunitinib ou de l'erlotinib
WO2012003421A2 (fr) * 2010-07-01 2012-01-05 Arqule, Inc. Compositions et procédés combinatoires de traitement du cancer
TW201221126A (en) * 2010-09-01 2012-06-01 Arqule Inc Methods for treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
BRPI1007972A2 (pt) 2016-09-13
EP2396003A2 (fr) 2011-12-21
WO2010093789A3 (fr) 2010-12-02
EP2396003B1 (fr) 2013-04-17
TW201043626A (en) 2010-12-16
JP2012517477A (ja) 2012-08-02
CA2752232A1 (fr) 2010-08-19
IL214348A0 (en) 2011-09-27
AU2010213696A1 (en) 2011-08-18
CN102481299A (zh) 2012-05-30
IL214348A (en) 2015-05-31
US20150328208A1 (en) 2015-11-19
WO2010093789A8 (fr) 2011-03-17
TWI460178B (zh) 2014-11-11
US9642847B2 (en) 2017-05-09
MX2011008584A (es) 2012-01-27
AU2010213696B2 (en) 2015-10-01
WO2010093789A2 (fr) 2010-08-19
JP5687209B2 (ja) 2015-03-18
CA2752232C (fr) 2016-11-22
KR20110118817A (ko) 2011-11-01
US20100297075A1 (en) 2010-11-25
ZA201105611B (en) 2012-10-31
CN102481299B (zh) 2015-02-25
KR101620654B1 (ko) 2016-05-12

Similar Documents

Publication Publication Date Title
HK1164159A1 (en) A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
IL212339A (en) Pyrolobenzodiazepine derivatives and processes for their preparation
ZA200806392B (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
EP2376659A4 (fr) Procédés, compositions et nécessaires de détection de variantes alléliques
ZA200805105B (en) Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
PL2373951T3 (pl) Pomiar średnicy na tokarkach
TWI347842B (en) Tricyclic compounds, compositions, and methods
PT2341933T (pt) Derivados de imidazoquinolina lipidados
EP2278879A4 (fr) Composés, compositions et traitements comprenant des dérivés d'oxydiazoles
GB0702259D0 (en) 7-azaindole derivatives
IL210171A0 (en) Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
GB0625842D0 (en) Indolizine derivatives
AP2010005202A0 (en) Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
IL205189A (en) 7,6-dihydro-h5-imidazo [2,1- α] imidazole-3-carboxamide and their pharmaceutical preparations
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
PL2283194T3 (pl) Zespół pojemnika możliwego do ryglowania
AP2010005521A0 (en) Macrocyclic indole derivatives useful as hepatitisvirus inhibitors.
IL195190A (en) 83cd soluble for use in combination therapy with immune suppressant
PT2014177E (pt) Combinação de hidrocoloides para textura inovadora
EP2310393A4 (fr) Artémisinine et dérivés de celle-ci en tant qu antiviraux
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
IL207223A0 (en) Pyrrolidinyl derivatives and uses thereof
PL2276347T3 (pl) Toltrazuril o ulepszonych właściwościach rozpuszczania
GB2464159B (en) Improvement in packaging
GB0702265D0 (en) 7-Azaindole derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180211